The optimal dosing schedule of G-CSF for peripheral blood progenitor cell (PBPC) mobilization is still under investigation although many centers use 10 g/kg/day in a single subcutaneous dose. However, G-CSF clearance increases with increasing absolute neutrophil count (ANC). Hence a G-CSF dosage adjusted to ANC might be a reasonable approach. We measured G-CSF trough serum levels by sandwich ELISA assay at different ANCs in eight patients undergoing treatment with filgrastim at 10 g/kg/day in a single subcutaneous dose. A total of 26 samples were analyzed, and a strong correlation between increasing ANC and decreasing G-CSF levels was found by linear regression analysis (P Ͻ 0.0003, r 2 = 0.4199). For ANC values above 5000/l the trough serum levels, ie 24 h after administration, were consistently below the level that provides maximal clonogenic precursor stimulation in vitro (10 ng/ml). Serial serum G-CSF measurements performed in three patients at 0, 3, 6, 9 and 24 h after G-CSF administration, showed a reduction of the area under the curve (AUC) with increasing ANC. For an ANC of 20 000/l or greater, the G-CSF serum level fell under the maximal in vitro stimulation threshold of 10 ng/ml within 12 h. This preliminary pharmacokinetic data seems to suggest that an ANC-adjusted G-CSF dosing schedule might improve the design of PBPC mobilization regimens. Keywords: granulocyte colony-stimulating factor; pharmacokinetics; peripheral blood progenitor cells; hematopoietic stem cell transplantation; CD34; administration There is no general agreement as to the optimal dosing schedule of rhG-CSF for the purpose of PBPC mobilization. Doses ranging from 2 g/kg/day to 60 g/kg/day starting at different time points prior to PBPC collection have been associated with PBPC mobilization.
Summary:
The optimal dosing schedule of G-CSF for peripheral blood progenitor cell (PBPC) mobilization is still under investigation although many centers use 10 g/kg/day in a single subcutaneous dose. However, G-CSF clearance increases with increasing absolute neutrophil count (ANC). Hence a G-CSF dosage adjusted to ANC might be a reasonable approach. We measured G-CSF trough serum levels by sandwich ELISA assay at different ANCs in eight patients undergoing treatment with filgrastim at 10 g/kg/day in a single subcutaneous dose. A total of 26 samples were analyzed, and a strong correlation between increasing ANC and decreasing G-CSF levels was found by linear regression analysis (P Ͻ 0.0003, r 2 = 0.4199). For ANC values above 5000/l the trough serum levels, ie 24 h after administration, were consistently below the level that provides maximal clonogenic precursor stimulation in vitro (10 ng/ml). Serial serum G-CSF measurements performed in three patients at 0, 3, 6, 9 and 24 h after G-CSF administration, showed a reduction of the area under the curve (AUC) with increasing ANC. For an ANC of 20 000/l or greater, the G-CSF serum level fell under the maximal in vitro stimulation threshold of 10 ng/ml within 12 h. This preliminary pharmacokinetic data seems to suggest that an ANC-adjusted G-CSF dosing schedule might improve the design of PBPC mobilization regimens. Keywords: granulocyte colony-stimulating factor; pharmacokinetics; peripheral blood progenitor cells; hematopoietic stem cell transplantation; CD34; administration There is no general agreement as to the optimal dosing schedule of rhG-CSF for the purpose of PBPC mobilization. Doses ranging from 2 g/kg/day to 60 g/kg/day starting at different time points prior to PBPC collection have been associated with PBPC mobilization. which is higher than the dose generally employed to treat granulocytopenia. 5 Other hematopoietic growth factors potentially active in mobilizing hematopoietic progenitors (interleukins 3 and 1, granulocyte-macrophage colony-stimulating factor, stem cell factor etc) are generally less well tolerated, have activities that may not be restricted to the hematopoietic system or might have the potential to stimulate the underlying malignancy. 11 Recombinant human G-CSF has been extensively studied and has been in clinical practice for more than 10 years. Its side-effects are mild and thoroughly characterized and it is well tolerated at doses up to 70 g/kg/day. 12, 13 Its activity seems to be restricted to the hematopoietic system, and there is no evidence so far that it might hasten tumor progression. Even though growth factor combinations might very effectively mobilize PBPC, 14 G-CSF as a single agent remains at present the most widely employed hematopoietic stimulating factor for this purpose. However, G-CSF pharmacokinetic properties have not been adequately taken into account in this context. The clearance of G-CSF varies with the neutrophil count, ie G-CSF clearance increases with increasing ANC. [15] [16] [17] In fact, the ANCdependent pharmacokinetics of G-CSF might be particularly relevant in the stem cell collection setting in which very high neutrophil counts (Ͼ20 000-30 000/l) are frequently reached. Thus a G-CSF dosage adjusted to ANC might provide a more rational approach in this context.
At the Children's Hospital of Florence we have analyzed G-CSF serum levels during mobilization in a group of pediatric cancer patients undergoing PBPC collection. To our knowledge this is the first study of G-CSF pharmacokinetics during PBPC mobilization.
Patients and methods

Patient characteristics
Eight patients with refractory or recurrent malignancies were studied. For patient characteristics see Table 1 . Informed consent was obtained from the patients or their parents. 
G-CSF serum levels
All samples were collected while patients were receiving filgrastim treatment at 10 g/kg/day in a single subcutaneous dose for the purpose of PBPC mobilization. Blood samples were kept at 4°C and serum was separated within 12 h of drawing. Serum samples were frozen and stored at Ϫ20°C until evaluation.
A total of 26 G-CSF trough serum samples, ie after 24 h from the last filgrastim administration, were obtained during the recovery phase (total white cell count Ͼ1000/l) from myelosuppressive chemotherapy in a total of 10 cycles (see Table 2 for details). The number of consecutive Table 2 Pre-mobilization treatment characteristics
No. Serum G-CSF levels were measured by sandwich ELISA assay (R&D Systems, Minneapolis, MN, USA). This assay detects both natural human and E. coli-derived recombinant human G-CSF, and lacks significant cross-reactivity with other cytokines. Appropriate dilutions were performed for samples expected to be potentially above the maximal sensitivity of the test (2500 pg/ml).
Based on our preliminary findings, in a poorly mobilizing heavily pretreated patient (patient No. 3, Table 1 ) with an ANC of 27 000/l and a falling CD34
+ peripheral blood count (from 14.3 ϫ 10 6 /l to 5 ϫ 10 6 /l), we increased the dose of filgrastim to 20 g/kg/day in two divided doses to attempt to raise the circulating CD34 + count to an acceptable range (Ͼ20 ϫ 10 antibody (HPCA2-FITC, Becton Dickinson, Erembodegem-Aalst, Belgium) or a negative control for background staining (isotype-specific fluorescent antibody). A minimum of 50 000 events were acquired with Becton Dickinson FACScan and analyzed with Lysis II software (Becton Dickinson).
Statistical analysis
Linear regression and correlation analysis were employed. Correlation significance was evaluated by two-tailed P values. For statistical analysis, AUC calculations and plotting GraphPad Prism software package was employed (GraphPad Software, San Diego, CA, USA).
Results
By linear regression analysis a strong correlation between increasing ANC and decreasing G-CSF trough levels was found (P Ͻ 0.0003, r 2 = 0.4199). The curve best representing the relationship between G-CSF trough levels and ANC is shown in Figure 1 . For ANC values above 5000/l, G-CSF serum trough levels were consistently below 10 ng/ml which is the level that provides maximal clonogenic precursor stimulation in vitro. /l), we were able to induce a new rise of circulating CD34 + count to an acceptable range (20.6 ϫ 10 6 /l) by increasing the dose of filgrastim to 20 g/kg/day in two divided dose (see Figure 4 ).
Discussion
That G-CSF clearance is dependent on the neutrophil count has been reported previously. [15] [16] [17] Our data is consistent with these observations and shows that the clearance of G- CSF is strikingly increased in the range on ANCs generally reached during PBPC collections (10 000 to 30 000/l). This phenomenon, which might be related to increased clearance deriving from neutrophil receptor binding, might provide the negative feedback required to down-modulate hematopoietic progenitor proliferation and neutrophil production. If considered in the context of PBPC mobilization strategies this mechanism might have very relevant implications.
In a patient with an insufficient stem cell collection by the time he had reached a high neutrophil count we were able to reverse a falling CD34
+ cell count by doubling the daily dose and giving it at a 12-h interval. This concept might be usefully applied in patients with poor marrow reserves in which high white counts are achieved before adequate PBPC numbers have been collected.
There is no uniform agreement as to the best G-CSF administration strategy for PBPC mobilization and further studies are needed. We believe that a G-CSF dosing schedule adjusted to neutrophil count is probably warranted and should be studied prospectively in large patient series. A dose of 2-5 g/kg in a single daily subcutaneous injection might be appropriate for ANCs below 500-1000/l, while it should be increased to 10 g/kg/day, in two divided doses or even as a continuous i.v. or s.c. infusion for higher ANCs. In fact, a 5 g/kg dose twice daily has been reported to be a potentially superior mobilizing regimen compared with 10 g/kg in a single dose. 10 Depending on the adequacy of PBPC mobilization the dose could be further escalated. On the other hand, this administration strategy might decrease total G-CSF utilization in most patients while not modifying or even potentially improving PBPC collections. The estimated cost of G-CSF for mobilization is of 1500-3000 US$, 18 most of which is administered at excessive doses in the neutropenic, pre-mobilization period in which G-CSF clearance is very low and thus very high levels are achieved. It can not be ruled out at present that these very high G-CSF levels (ӷ10 ng/ml) in the neutropenic period might be important to prime early progenitor cells, however it seems very unlikely; first because 10 ng/ml most probably saturates progenitor cell G-CSF receptors, second because it has been shown that G-CSF can be started at different time points after chemotherapy administration 19, 20 with adequate PBPC mobilizations. The superiority of 10 g/kg over 5 g/kg in the PBPC mobilization setting might be due entirely to an effect restricted to higher G-CSF levels during the relatively few but critical days of ANC Ͼ 5000-10 000/l in which 5 g/kg in a single daily dose is not sufficient to maintain mobilizing serum G-CSF levels (possibly above 10 ng/ml).
In conclusion, these preliminary pharmacokinetic data seem to suggest that an ANC-adjusted G-CSF dosing schedule might be the most rational approach to the design of PBPC mobilization regimens. It may have the potential to increase hematopoietic stem cell collections in heavily pretreated patients and to improve the cost-effectiveness of G-CSF-based PBPC mobilization.
